Cargando…
The miR-644a/CTBP1/p53 axis suppresses drug resistance by simultaneous inhibition of cell survival and epithelial-mesenchymal transition in breast cancer
Tumor cells develop drug resistance which leads to recurrence and distant metastasis. MicroRNAs are key regulators of tumor pathogenesis; however, little is known whether they can sensitize cells and block metastasis simultaneously. Here, we report miR-644a as a novel inhibitor of both cell survival...
Autores principales: | Raza, Umar, Saatci, Özge, Uhlmann, Stefan, Ansari, Suhail A, Eyüpoğlu, Erol, Yurdusev, Emre, Mutlu, Merve, Ersan, Pelin Gülizar, Altundağ, Mustafa Kadri, Zhang, Jitao David, Doğan, Hayriye Tatlı, Güler, Gülnur, Şahin, Özgür |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226553/ https://www.ncbi.nlm.nih.gov/pubmed/27409664 http://dx.doi.org/10.18632/oncotarget.10489 |
Ejemplares similares
-
miR-564 acts as a dual inhibitor of PI3K and MAPK signaling networks and inhibits proliferation and invasion in breast cancer
por: Mutlu, Merve, et al.
Publicado: (2016) -
miR-644a Inhibits Cellular Proliferation and Invasion via Suppression of CtBP1 in Gastric Cancer Cells
por: Li, Yingchao, et al.
Publicado: (2018) -
Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer
por: Saatci, Ozge, et al.
Publicado: (2020) -
Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4/6 inhibitors in treatment-refractory ER+ breast cancer
por: Saatci, Ozge, et al.
Publicado: (2023) -
CTBP1 and CTBP2 mutations underpinning neurological disorders: a systematic review
por: Acosta-Baena, Natalia, et al.
Publicado: (2022)